# Advancements in obesity and diabetes medications > Live situation record from CLSTR: https://clstr.news/situations/advancements-in-obesity-and-diabetes-medications > Updated: 2026-10-02T09:56:43.000Z. Sources: 6. Developments: 2. Developments in obesity and diabetes treatments have focused on both regulatory approvals and clinical efficacy data. In Brazil, the National Health Surveillance Agency (Anvisa) approved generic registrations for liraglutide, a GLP-1 receptor agonist manufactured by EMS. These generic subcutaneous injectable solutions are intended to reduce costs for obesity and type 2 diabetes patients by being priced at least 35% lower than reference products. Concurrently, clinical data presented at the EASD 2026 congress highlighted advancements in metabolic health and weight reduction. Phase 3 trials for retatrutide showed participants achieving an average weight loss of 28.3% over 80 weeks, with some studies showing significant reductions in HbA1c levels for type 2 diabetes patients. Additionally, the combination treatment CagriSema demonstrated weight loss efficacy in both obesity and diabetes studies, while also impacting neurological hunger cues and ‘food noise’. ## Timeline ### 2026-10-02: Obesity drugs show up to 30% weight loss at EASD 2026 New data from the EASD 2026 congress in Milan shows obesity drugs like retatrutide and CagriSema can achieve weight loss of nearly 30% while reducing hunger and improving metabolic health. 3 sources. https://clstr.news/cluster/obesity-drugs-show-up-to-30-weight-loss-at-easd-2026 ### 2026-09-08: Anvisa approves generic obesity and diabetes medications from EMS Anvisa has approved two generic liraglutide medications from EMS for treating obesity and type 2 diabetes in Brazil, a move expected to increase market competition and lower costs. 3 sources. https://clstr.news/cluster/anvisa-approves-generic-obesity-and-diabetes-medications-from-ems --- Cite as: Advancements in obesity and diabetes medications. CLSTR, https://clstr.news/situations/advancements-in-obesity-and-diabetes-medications